ArticleMolecular cancer therapeutics2017
TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
Open access · greenAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.The Journal of clinical investigation · 2026Review
- Epigenetic control of topoisomerase 1 activity presents a cancer vulnerability.Nature communications · 2025Article
- Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency.Molecular cancer therapeutics · 2025Article
- New Hybrid Compounds Combining Fragments of Usnic Acid and Thioether Are Inhibitors of Human Enzymes TDP1, TDP2 and PARP1.International journal of molecular sciences · 2021Article
- Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.Journal of experimental & clinical cancer research : CR · 2021Article
- A Dual-Sensor-Based Screening System for In Vitro Selection of TDP1 Inhibitors.Sensors (Basel, Switzerland) · 2021Article
- Critical roles of Rad54 in tolerance to apigenin-induced Top1-mediated DNA damage.Experimental and therapeutic medicine · 2021Article
- Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation.Cell death & disease · 2020Article
- Participation of TDP1 in the repair of formaldehyde-induced DNA-protein cross-links in chicken DT40 cells.PloS one · 2020Article
- CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death.Molecular cancer therapeutics · 2019Article
- Tyrosyl-DNA Phosphodiesterase I N-Terminal Domain Modifications and Interactions Regulate Cellular Function.Genes · 2019Review
- Dual Processing of R-Loops and Topoisomerase I Induces Transcription-Dependent DNA Double-Strand Breaks.Cell reports · 2019Article
- Mammalian Tyrosyl-DNA Phosphodiesterases in the Context of Mitochondrial DNA Repair.International journal of molecular sciences · 2019Review
- Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts.Cancer drug resistance (Alhambra, Calif.) · 2019Article
- Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs.Cancer drug resistance (Alhambra, Calif.) · 2019Article
- TDP1 suppresses mis-joining of radiomimetic DNA double-strand breaks and cooperates with Artemis to promote optimal nonhomologous end joining.Nucleic acids research · 2018Article
- PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes.Nucleic acids research · 2018Article
- Tyrosyl-DNA phosphodiesterases: rescuing the genome from the risks of relaxation.Nucleic acids research · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Muthana Al AboDevelopmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Hiroyuki SasanumaDepartment of Radiation Genetics, Kyoto University, Graduate School of Medicine, Yoshida Konoe, Sakyo-ku, Kyoto, Japan.
Xiaojun LiuDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Vinodh N RajapakseDevelopmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Shar-Yin HuangDevelopmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Evgeny KiselevDevelopmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Shunichi TakedaDepartment of Radiation Genetics, Kyoto University, Graduate School of Medicine, Yoshida Konoe, Sakyo-ku, Kyoto, Japan.
William PlunkettDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Yves PommierDevelopmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. pommier@nih.gov.
The University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MDNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer DrugsZIABC006150 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 2009 to 2025
$23.0MBIOCHEMICAL BASIS FOR THERAPEUTIC ACTIVITYR01CA028596 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PLUNKETT, WILLIAM K · 1985 to 2015
$3.0MPROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITIONZ01BC006150 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 1996 to 2008
$1.5MIntramural NIH HHS Z01 BC006150NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA028596
Abstract
2'-
Indexed as
ArabinonucleosidesBRCA2 ProteinCamptothecinColorectal NeoplasmsCytarabineCytosineDNA Breaks, Single-StrandedDNA DamageDNA RepairDNA ReplicationGene Expression Regulation, NeoplasticHCT116 CellsHumansPhosphoric Diester HydrolasesPoly (ADP-Ribose) Polymerase-12'-cyano-2'-deoxyarabinofuranosylcytosineArabinonucleosidesBRCA2 ProteinBRCA2 protein, humanCamptothecinCytarabineCytosinePARP1 protein, humanPhosphoric Diester HydrolasesPoly (ADP-Ribose) Polymerase-1sapacitabineTDP1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.